idarucizumab Injection [Praxbind]
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
RE-VERSE AD, a prospective multicentric cohort study, examined the effect of idarucizumab on 2 cohorts of patients anticoagulated…
ABSTRACT The number of novel antibody therapeutics that received first marketing approvals in 2015 met expectations, with 6…
Although clinical trials have shown that bleeding rates associated with the use of target-specific oral anticoagulant drugs are…
Dabigatran, an oral anticoagulant that acts by inhibiting thrombin, was first marketed in the European Union in 2008. No antidote…
Idarucizumab (Praxbind®) is a fully humanized, monoclonal antibody fragment developed by Boehringer Ingelheim as a specific…
espanolSe resenan los medicamentos evaluados y con dictamen positivo por comision de expertos de la Agencia Espanola de…